Completed PHASE2 INTERVENTIONAL 3-arm NCT02326961

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee (ACT-OA Knee)

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study

Sponsor: Cytori Therapeutics

Conditions Osteoarthritis, Knee

Interventions Celution Device Placebo

Updated 6 times since 2017 Last updated: Oct 26, 2016 Started: Jan 31, 2015 Primary completion: Jun 30, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02326961, this PHASE2 trial focuses on Osteoarthritis, Knee and remains completed. Sponsored by Cytori Therapeutics, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cytori Therapeutics

Data source: Cytori Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chicago, United States , Covington, United States , Duncansville, United States , Frederick, United States , Kansas City, United States , La Mesa, United States , Lexington, United States , Little Rock, United States , Mesa, United States , New York, United States and 1 more location